Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.43 |
| ▸ | USP2 | O75604 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30733398 | 0.87 | ACLY (0.43) | CYP3A4CYP2C9CYP2C19TP53ACLY | |
| SCHEMBL30733427 | 0.86 | ACLY (0.42) | CYP3A4CYP2C9CYP2C19TP53ACLY | |
| SCHEMBL26969776 | 0.85 | ACLY (0.41) | CYP3A4CYP2C9CYP2C19ACLYNPY5R | |
| SCHEMBL25237936 | 0.85 | ACLY (0.41) | CYP3A4CYP2C9CYP2C19ACLYNPY5R | |
| SCHEMBL25237931 | 0.84 | ACLY (0.41) | CYP3A4ALDH1A1CYP2C9CYP2C19ACLY | |
| SCHEMBL25231978 | 0.83 | ACLY (0.40) | CYP3A4CYP2C9CYP2C19ACLYNPY5R | |
| SCHEMBL25274911 | 0.83 | NPY5R (0.43) | ALDH1A1NPY5RTACR1 | |
| SCHEMBL26969744 | 0.83 | HTR6 (0.40) | ACLYNPY5RTACR1 | |
| SCHEMBL25274228 | 0.83 | NPY5R (0.46) | ALDH1A1SMN1; SMN2ACLYNPY5RTACR1 | |
| SCHEMBL26969733 | 0.82 | NPY5R (0.60) | ALDH1A1NPY5RTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CYP3A4 2481/4885ALDH1A1 3737/4885CYP1A2 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.